Shares of Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $10.99 and traded as low as $6.21. Prothena shares last traded at $6.47, with a volume of 636,811 shares traded.
Analyst Ratings Changes
PRTA has been the topic of a number of research analyst reports. Cantor Fitzgerald restated a "neutral" rating on shares of Prothena in a research report on Friday, June 20th. Chardan Capital reduced their price objective on shares of Prothena from $40.00 to $18.00 and set a "buy" rating on the stock in a report on Tuesday, May 27th. Piper Sandler lowered their target price on shares of Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research note on Tuesday, May 27th. JMP Securities dropped their price target on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating for the company in a research report on Tuesday, May 27th. Finally, Oppenheimer downgraded shares of Prothena from an "outperform" rating to a "market perform" rating in a research note on Tuesday, May 27th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $31.50.
Check Out Our Latest Stock Report on Prothena
Prothena Price Performance
The company has a market capitalization of $348.26 million, a PE ratio of -3.11 and a beta of 0.01. The stock's 50 day simple moving average is $6.46 and its 200-day simple moving average is $10.99.
Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.20). Prothena had a negative net margin of 79.94% and a negative return on equity of 21.61%. The business had revenue of $2.83 million during the quarter, compared to analysts' expectations of $8.18 million. During the same period in the previous year, the business posted ($1.34) EPS. The company's revenue for the quarter was up 5500.0% compared to the same quarter last year. On average, equities analysts predict that Prothena Corporation plc will post -4.04 earnings per share for the current year.
Hedge Funds Weigh In On Prothena
Institutional investors have recently modified their holdings of the business. Virtus ETF Advisers LLC raised its stake in shares of Prothena by 19.3% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock valued at $71,000 after acquiring an additional 833 shares in the last quarter. GAMMA Investing LLC increased its holdings in Prothena by 4,626.0% during the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company's stock worth $74,000 after purchasing an additional 5,875 shares during the period. Headlands Technologies LLC raised its position in Prothena by 196.5% in the 4th quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 4,858 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Prothena in the 1st quarter valued at about $126,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of Prothena in the 4th quarter valued at about $145,000. Institutional investors and hedge funds own 97.08% of the company's stock.
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Stories
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
